Open AccessLong non‐coding RNA KDM5B anti‐sense RNA 1 enhances tumor progression in non‐small cell lung cancer
Author(s) -
Lou Baisong,
Wei Dongwei,
Zhou Xin,
Chen Hong
Publication year - 2020
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22897
Subject(s) - long non coding rna , biology , rna , cancer research , immunostaining , lung cancer , sense (electronics) , cell growth , non coding rna , apoptosis , metastasis , cell , in vivo , cancer , immunohistochemistry , medicine , immunology , gene , pathology , genetics , chemistry
Background The long non‐coding RNAs (lncRNAs) have been shown as a novel class of transcripts with no protein coding functions. LncRNAs can play diverse roles in cancer cell proliferation, differentiation, metastasis, and apoptosis. However, the exact contributions of lncRNA KDM5B anti‐sense RNA 1 (KDM5BAS1) to non‐small cell lung cancer (NSCLC) remain poorly understood. Methods In current study, we have unraveled a novel function of KDM5BAS1 in NSCLC. Results We found that KDM5BAS1 was significantly overexpressed in tumor specimens and selected cancerous cell lines. Meanwhile, higher KDM5BAS1 expression predicted poor overall survival. Increased KDM5BAS1 expression can promote proliferation or migration and inhibit apoptosis in H1838 and H1299 cells. Furthermore, knocking down of KDM5BAS1 levels can also reduce tumor growth in in vivo implantation experiments. Overexpression of KDM5BAS1 also decreased the caspase‐3 immunostaining but enhanced Ki‐67 staining. Conclusion Taken together, our findings indicated that KDM5BAS1 might play an oncogenic role in NSCLC and provided clues into pharmacological intervention targeting KDM5BAS1.